Long-term oncological outcomes of indocyanine green fluorescence imaging-guided laparoscopic lymphadenectomy for gastric cancer: 5-year outcomes from the FUGES-012 randomized clinical trial.

Background: The clinical use of indocyanine green (ICG) in laparoscopic radical gastrectomy for gastric cancer remains at an exploratory stage.

Methods: Participants with resectable gastric adenocarcinoma were randomly allocated in a 1:1 ratio. The primary outcome is the number of retrieved lymph nodes (LNs) and has been reported.

Enhancing prognostic accuracy in gastric cancer: The TNrrM staging system versus the AJCC TNM system.

Background: An accurate staging system is crucial for the management of gastric cancer (GC) patients. This study aimed to propose a novel staging system (TNrrM) based on the regional lymph node ratio (rLNR), defined as the ratio of the number of metastatic lymph nodes (LNs) to the number of examined LNs within each LN station.

Methods: The study included 3263 GC patients, with 2143 in the development set and 1120 in the validation set.

Assessment of the safety and efficacy of robotic versus laparoscopic gastrectomy in overweight patients with gastric cancer: a large-scale multicenter cohort study.

Background: The comparative efficacy of robotic (RG) and laparoscopic gastrectomy (LG) in patients with gastric cancer with a body mass index (BMI) ≥ 25 kg/m remains unclear. We compared the outcomes between RG and LG in this patient population.

Methods: This multicenter cohort study included 695 patients with gastric cancer with BMI ≥ 25 kg/m who underwent RG (n = 220) or LG (n = 475) at eight high-volume teaching hospitals in China.

Assessment of robotic versus laparoscopic gastrectomy for gastric cancer patients with intraoperative technical complexity a multicenter retrospective study.

Background: While robotic gastrectomy (RG) is increasingly used in gastric cancer surgery, its potential advantages over laparoscopic gastrectomy (LG) in intraoperative technical complexity (ITC) cases remain debated.

Methods: This retrospective cohort study included 3,534 patients with gastric cancer who underwent radical gastrectomy at eight high-volume hospitals. ITC was defined by any of the following criteria: operative time exceeding the third quartile, intraoperative estimated blood loss ≥ 400 mL, or conversion to open surgery.

Comparison of short- and mid-term outcomes of robotic versus laparoscopic gastrectomy in high-risk patients with gastric cancer: a nationwide, multicentre cohort study.

Background: To compare short-term and mid-term outcomes of robotic gastrectomy (RG) versus laparoscopic gastrectomy (LG) in high-risk gastric cancer (GC) patients.

Methods: Patients with ≥1 of the following criteria were defined as high-risk: age ≥80 years; BMI ≥30 kg/m; ASA grade ≥ III; and clinical T stage (cT4). Finally, 2001 patients who underwent radical gastrectomy between August 2016 and June 2019 at eight high-volume hospitals were included and underwent 1:1 propensity score matching (PSM) with 534 patients in each group.

Long-term outcomes of laparoscopic distal gastrectomy for locally advanced gastric cancer: An individual patient data meta-analysis of KLASS-02 and CLASS-01 randomized controlled trials.

Objective: Laparoscopic distal gastrectomy (LDG) has potential as a surgical treatment option for locally advanced gastric cancer (LAGC). However, there is uncertainty regarding the generalizability of LDG efficacy across diverse patient populations and treatment settings. This study aimed to assess the outcomes of LDG .

Predicting the prognosis of radical gastrectomy for patients with locally advanced gastric cancer after neoadjuvant chemotherapy using machine learning technology: a multicenter study in China.

Background: Neoadjuvant chemotherapy (NAC) can improve the prognosis of patients with locally advanced gastric cancer (LAGC). However, precise models for accurate prognostic predictions are lacking. We aimed to utilize Cox regression and integrate various machine learning (ML) algorithms to identify and prioritize key factors influencing LAGC overall survival to establish an efficient prognostic prediction model.

Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping: Chemotherapy, Immunotherapy, or Targeted Therapy?-A Retrospective Analysis.

Background: This study aimed to identify the most effective drug therapeutics for patients with the mesenchymal subtype of advanced gastric cancer (AGC). Extensive research employing diverse omics methodologies has unveiled a varied landscape of AGC. Recent progress in next-generation sequencing and other genomic technologies has facilitated a more intricate exploration of AGC at the molecular level.

Nonablative Fractional 1927-nm Laser for Periorbital Rejuvenation: A Prospective, Double-Arm, Open-Label Trial.

Background: The 1927-nm nonablative fractional laser is widely used for skin rejuvenation and hyperpigmentation. However, its efficacy and safety for periorbital rejuvenation remain uncertain.

Aims: To assess the effects of the 1927-nm nonablative fractional diode laser on periorbital rejuvenation.

Appraisal of Residual Tumor Burden on Survival Prognosis Following Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer: A Multicenter Cohort Study.

Background: The eighth edition American Joint Committee on Cancer (AJCC) guidelines introduced the postneoadjuvant therapy pathologic tumor, node, metastasis (ypTNM) staging system to assess gastric cancer prognosis postneoadjuvant chemotherapy; however, it overlooks other residual tumor burden aspects beyond tumor infiltration depth and positive lymph nodes.

Methods: Data from 537 locally advanced gastric cancer patients (cT2-4NanyM0) treated with neoadjuvant chemotherapy (2010-2021) across six tertiary centers were analyzed. Prognostic factors for overall survival (OS) and recurrence-free survival (RFS) were identified using Cox regression.

Development and validation of a novel modified cancer cachexia index in patients with locally advanced gastric cancer undergoing neoadjuvant chemotherapy: a multicenter cohort study.

Background: Although the cachexia index(CXI) is a well established prognostic predictor in gastric cancer(GC) patients, its effectiveness in patients with locally advanced gastric cancer(LAGC) who have undergone neoadjuvant chemotherapy(NACT) remains unclear.

Methods: This multicenter study included 600 LAGC patients treated with NACT from January 2010 to June 2022. A modified CXI was constructed based on Random Forest model, calculated as (post-NACT subcutaneous adipose tissue area at L3) ×(post-NACT serum albumin)/(post-NACT platelet count).

Chinese expert consensus on failure and revision after anterior cruciate ligament reconstruction.

Background: With the recent rise in anterior cruciate ligament (ACL) reconstruction surgeries in China, a corresponding increase in surgical failures has been observed. Variability in primary surgical techniques and the intricacies of failure mechanisms have introduced significant challenges in diagnosing failures, planning procedures, and conducting revision surgeries.

Methods: In response to these challenges, the Chinese Association of Orthopaedic Surgeons (CAOS) and the Chinese Society of Sports Medicine (CSSM) initiated the development of an expert consensus on ACL reconstruction failure and revision.

The impact of surgical case order on short- and long-term outcomes in patients undergoing laparoscopic gastrectomy: a propensity matched study.

Background: Whether the surgical case order is an important factor affecting the short- and long-term outcomes of patients with gastric cancer (GC) has always been a concern. This study aimed to compare the short- and long-term outcomes of different surgical case orders.

Methods: This study included patients who underwent laparoscopy-assisted radical gastrectomy at the Union Hospital of Fujian Medical University between January 2016 and December 2017.

Safety and efficacy of indocyanine green-guided laparoscopic lymphadenectomy for locally advanced gastric cancer: The CLASS-11 clinical trials.

We report the short-term results of indocyanine green (ICG)-guided laparoscopic lymphadenectomy for gastric cancer (GC). The primary outcome is 3-year disease-free survival. In this analysis, we present short-term secondary outcomes focused on the number of lymph nodes (LNs) retrieved and the diagnostic value of fluorescent status for metastatic LNs, excluding long-term outcomes.

Surgical and oncological outcomes of laparoscopic versus open gastrectomy after neoadjuvant chemotherapy in patients with locally advanced gastric cancer: A multicenter analysis.

Background: Evidence based on large-scale samples comparing the efficacy of laparoscopic gastrectomy (LG) and open gastrectomy (OG) in patients with locally advanced gastric cancer (LAGC) after neoadjuvant chemotherapy (NACT) remains limited. This multicenter study aimed to evaluate the short -term and oncological outcomes of LG and OG after NACT.

Methods: Data from a multicenter database of LAGC patients undergoing radical gastrectomy after NACT across 12 centers in China.

Optimal response population after neoadjuvant therapy for patients with locally advanced gastric cancer: A multicenter study.

Objective: Pathologic complete response (pCR) following neoadjuvant therapy (NAT) for gastric cancer (GC) is rare but associated with a favorable prognosis. This study aims to reassess the optimal response population (ORP) following NAT by evaluating the prognostic outcomes associated with various T and N stages, utilizing multicenter data from China.

Methods: Patients who underwent NAT following radical gastrectomy at 10 tertiary hospitals in China between 2008 and 2021 were included.

Paradoxical effects of adiposity and inflammation on immunotherapy efficacy in gastric cancer: novel insights from real-world data.

Background: Emerging studies suggest obesity may improve PD-1/PD-L1 inhibitor efficacy, correlating with prolonged survival, known as the 'obesity paradox'. However, the impact of this paradox and obesity-related chronic inflammation on immunotherapy for advanced gastric cancer (AGC) has not received sufficient research.

Methods: Between January 2018 and December 2021, patients receiving neoadjuvant therapy were categorized into two groups: combined immunotherapy (ICIs, n = 173) and neoadjuvant chemotherapy (NAC, n = 126).

Comparison of short- and long-term outcomes for robotic versus laparoscopic gastrectomy in elderly patients with gastric cancer: a multicenter cohort study.

Background: There is limited evidence from large-scale multicenter studies regarding the short- and long-term efficacy of robotic gastrectomy (RG) in elderly patients diagnosed with gastric cancer (GC). As such, this retrospective investigation compared short-term outcomes and long-term oncological prognoses of RG versus (vs.) laparoscopic gastrectomy (LG) in a representative sample of this population.

Comprehensive comparison of technical performance, surgical outcomes, and oncologic prognosis between remnant gastric cancer and primary upper-third gastric cancer in the era of minimally invasive surgery: A pooled analysis of 3 prospective trials.

Background And Objective: To compare the technical performances and short- and long-term outcomes of laparoscopic total gastrectomy for remnant gastric cancer and primary upper gastric cancer.

Methods: This prospective study (FUGES-004 study) enrolled 50 remnant gastric cancer patients who underwent laparoscopic total gastrectomy at Fujian Medical University Union Hospital between June 2016 and June 2020 (ClinicalTrials.gov identifier: NCT02792881).

Timing of postoperative chemotherapy and prognosis in neoadjuvant-treated gastric cancer patients: a multicenter real-world cohort study.

Background: The optimal time to chemotherapy (TTC) in locally advanced gastric cancer (LAGC) patients treated with neoadjuvant chemotherapy (NLAGC) remains unclear.

Methods: Consecutive 524 patients with NLAGC between Jan. 2010 and Dec.

Patterns of Survival and Recurrence in Poor Responders to Neoadjuvant Therapy for Gastric Cancer: A Real-World Multicenter Study.

Background: Neoadjuvant therapy (NAT) is increasingly used in locally advanced gastric cancer (LAGC), but a significant proportion of patients respond poorly, causing adverse outcomes. Few studies have specifically examined the prognosis of this subgroup. This study aimed to analyze survival and recurrence in poor responders to guide follow-up and treatment strategies.

The minimum number of lymph node retrieval in gastric cancer patients after neoadjuvant therapy: An international multi-institute cohort study.

Background: The minimum number of retrieved lymph nodes for radical gastrectomy after neoadjuvant therapy remains controversial. The objective of this study was to determine the minimum threshold for retrieved lymph nodes in patients with gastric cancer after neoadjuvant therapy to accurately evaluate staging and prognosis.

Methods: Multivariate models were employed to investigate the correlation between the number of retrieved lymph nodes and survival outcomes and stage migration.

marks gastric corpus progenitors that give rise to pyloric metaplasia/SPEM following injury.

In Brief: Tu et al. show that Tff2 corpus isthmus cells are TA progenitors, and they, not chief cells, are the primary source of SPEM following injury. Upon Kras mutation, these progenitors directly progress to dysplasia, bypassing metaplasia, highlighting them as a potential origin of gastric cancer.

Targeting LHPP in neoadjuvant chemotherapy resistance of gastric cancer: insights from single-cell and multi-omics data on tumor immune microenvironment and stemness characteristics.

Gastric cancer (GC) is a highly heterogeneous and complex malignancy, often characterized by tumor stemness and immune evasion mechanisms, which contribute to a poor response to neoadjuvant chemotherapy (NAC) and treatment resistance. In this study, we performed a comprehensive analysis using single-cell and multi-omics approaches on 375 GC samples from The Cancer Genome Atlas database, along with 141 clinical samples from patients who underwent NAC. We identified key gene modules associated with stemness and immune traits, and developed a novel stem cell-immune risk score.

Multi-cohort study in gastric cancer to develop CT-based radiomic models to predict pathological response to neoadjuvant immunotherapy.

Background: Neoadjuvant immunotherapy has been shown to improve survival in patients with gastric cancer. This study sought to develop and validate a radiomics-based machine learning (ML) model for patients with locally advanced gastric cancer (LAGC), specifically to predict whether patients will achieve a major pathological response (MPR) following neoadjuvant immunotherapy. With its predictive capabilities, this tool shows promise for enhancing clinical decision-making processes in the future.